$2.400
-0.087 (-3.61%)Zum Schluss
EDIT-News
EDIT-Events
Editas Medicine Receives Approval to Initiate EDIT-401 Clinical Trial
Editas Medicine announced it has received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia, or HeFH, in Australia. The trial has received Human Research Ethics Committee, or HREC, approval and completed the Clinical Trial Notification, or CTN, process with Australia's Therapeutic Goods Administration, or TGA, and has also been submitted for review in New Zealand. If approved in New Zealand, patients in both countries will be eligible to enroll in the Strive trial. The company also announced that new preclinical data, demonstrating durability of LDL-C reduction with EDIT-401, will be released via an oral presentation at the American Heart Association, or AHA, Scientific Sessions 2026, taking place November 6-9, in Chicago, Illinois. Editas expects to report initial safety and tolerability data in the first quarter of 2027. The company plans to complete enrollment in Part 1, the dose-finding portion of the Phase 1/2 trial of EDIT-401, with topline safety and efficacy data results available later in 2027.
Editas Medicine Shares Drop Nearly 5%
Editas Medicine (EDIT) is trading lower alongside other gene editing peers after Anthropic shared early findings on a CRISPR like enzyme system. Anthropic said its Claude model autonomously identified a previously uncharacterized enzyme system associated with DNA repeat arrays, a pattern reminiscent of CRISPR. While the function of the system is not yet known, the company noted that its characteristics resemble those found in programmable DNA editing tools. Shares of Editas are down almost 5% in afternoon trading.
Editas Medicine Appoints Dan Ory as Chief Medical Officer
Editas Medicine announced the appointment of Dan Ory as chief medical officer, effective immediately. Ory will oversee the company's clinical development strategy and operations as Editas advances EDIT-401, its lead in vivo development candidate for the potential treatment of hyperlipidemia, toward the clinic, while supporting the progression of the company's broader pipeline. Prior to joining Editas, Ory served as chief medical officer at Arbor Biotechnologies.
Editas Medicine Files $400M Mixed Securities Shelf
Editas Medicine files $400M mixed securities shelf
Editas Medicine Reports Q2 Revenue of $11.89M, Exceeding Expectations
Reports Q2 revenue $11.89M, consensus $2.75M. The revenue increase was primarily attributable to the recognition of deferred revenue related to the expiration certain rights to opt-in to additional research programs under its collaboration with BMS. "During the second quarter, we continued preclinical work to support advancing EDIT-401 into a single ascending dose, open-label Phase 1/2 study," said Gilmore O'Neill, President and Chief Executive Officer of Editas Medicine. "We also presented new preclinical data demonstrating the ability of a single dose of EDIT-401 to achieve rapid and significant reductions in multiple atherogenic lipoproteins in non-human primates along with a promising preclinical safety profile, reinforcing EDIT-401's potential as a best-in-class, one-time treatment for hyperlipidemia. In addition, with our recent equity financing, we are well capitalized to drive the clinical development of EDIT-401 through key value-creating milestones. We look forward to our continued progress and expect to provide a data update in the first quarter of 2027."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.